Last reviewed · How we verify
Clarithromycin DST (250 mg)
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial respiratory tract infections, Helicobacter pylori eradication (as part of combination therapy), Atypical mycobacterial infections.
At a glance
| Generic name | Clarithromycin DST (250 mg) |
|---|---|
| Sponsor | Grünenthal GmbH |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Clarithromycin binds irreversibly to the bacterial 50S ribosomal subunit, blocking peptide translocation and inhibiting protein synthesis. This bacteriostatic action prevents bacterial growth and replication. The drug is effective against a broad spectrum of gram-positive and some gram-negative bacteria, as well as atypical organisms.
Approved indications
- Bacterial respiratory tract infections
- Helicobacter pylori eradication (as part of combination therapy)
- Atypical mycobacterial infections
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Headache
- Taste disturbance
- QT prolongation
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |